WO2019216568A1 - 상아질 지각과민증 완화를 위한 치약 조성물 - Google Patents
상아질 지각과민증 완화를 위한 치약 조성물 Download PDFInfo
- Publication number
- WO2019216568A1 WO2019216568A1 PCT/KR2019/004636 KR2019004636W WO2019216568A1 WO 2019216568 A1 WO2019216568 A1 WO 2019216568A1 KR 2019004636 W KR2019004636 W KR 2019004636W WO 2019216568 A1 WO2019216568 A1 WO 2019216568A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- peptide
- dentin
- parts
- amino acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 201000002170 dentin sensitivity Diseases 0.000 title claims abstract description 48
- 229940034610 toothpaste Drugs 0.000 title claims abstract description 42
- 239000000606 toothpaste Substances 0.000 title claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 155
- 150000001413 amino acids Chemical group 0.000 claims abstract description 69
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000004472 Lysine Substances 0.000 claims abstract description 34
- 239000004475 Arginine Substances 0.000 claims abstract description 29
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 29
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 16
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims abstract description 4
- 229960001230 asparagine Drugs 0.000 claims abstract description 4
- 235000009582 asparagine Nutrition 0.000 claims abstract description 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims abstract description 3
- 210000004268 dentin Anatomy 0.000 claims description 53
- 210000005239 tubule Anatomy 0.000 claims description 27
- 239000000551 dentifrice Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 239000008213 purified water Substances 0.000 claims description 11
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 10
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 9
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 8
- 239000001506 calcium phosphate Substances 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 7
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 7
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- 229960002920 sorbitol Drugs 0.000 claims description 6
- 229940098465 tincture Drugs 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 5
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 4
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 4
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 4
- 244000042664 Matricaria chamomilla Species 0.000 claims description 4
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 4
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 4
- 241000241413 Propolis Species 0.000 claims description 4
- 229960000458 allantoin Drugs 0.000 claims description 4
- 229940119217 chamomile extract Drugs 0.000 claims description 4
- 235000020221 chamomile extract Nutrition 0.000 claims description 4
- 229940107702 grapefruit seed extract Drugs 0.000 claims description 4
- 229940094952 green tea extract Drugs 0.000 claims description 4
- 235000020688 green tea extract Nutrition 0.000 claims description 4
- 239000013521 mastic Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 229940069949 propolis Drugs 0.000 claims description 4
- 229940092258 rosemary extract Drugs 0.000 claims description 4
- 235000020748 rosemary extract Nutrition 0.000 claims description 4
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 240000007311 Commiphora myrrha Species 0.000 claims description 3
- 241001133829 Latania Species 0.000 claims description 3
- 244000024873 Mentha crispa Species 0.000 claims description 3
- 235000014749 Mentha crispa Nutrition 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 3
- 235000019477 peppermint oil Nutrition 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- 239000010409 thin film Substances 0.000 claims description 2
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 71
- 235000001014 amino acid Nutrition 0.000 description 71
- 102000004196 processed proteins & peptides Human genes 0.000 description 60
- 108020004999 messenger RNA Proteins 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 37
- 230000000694 effects Effects 0.000 description 36
- 230000004069 differentiation Effects 0.000 description 35
- 101150106419 Dspp gene Proteins 0.000 description 28
- 101000865404 Homo sapiens Dentin sialophosphoprotein Proteins 0.000 description 27
- 210000004416 odontoblast Anatomy 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 17
- 239000003550 marker Substances 0.000 description 15
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 210000000287 oocyte Anatomy 0.000 description 13
- 102100029792 Dentin sialophosphoprotein Human genes 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 10
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 230000009610 hypersensitivity Effects 0.000 description 9
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 7
- 239000000120 Artificial Saliva Substances 0.000 description 7
- 101150081193 DMP1 gene Proteins 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- 108010088225 Nestin Proteins 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 6
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- -1 Leu / Val Chemical compound 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004770 highest occupied molecular orbital Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WZIMSXIXZTUBSO-UHFFFAOYSA-N 2-[[bis(carboxymethyl)amino]methyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CN(CC(O)=O)CC(O)=O WZIMSXIXZTUBSO-UHFFFAOYSA-N 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108091033411 PCA3 Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 108010088492 dentin sialophosphoprotein Proteins 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Definitions
- the present invention relates to a dentifrice composition, and more particularly, the present invention relates to a dentifrice composition for preventing or alleviating hypersensitivity by inducing physiological remineralization of dentin defects constituting teeth.
- Dentinic hypersensitivity commonly referred to as 'single'
- 'single' Dentinic hypersensitivity
- 'single' is a common symptom experienced by 8% to 57% of the adult population.
- 72.5% to 98% of patients suffer from sickness (Source: National Health Information Portal Medical Information; http://health.cdc.go.kr/health /Main.do).
- Dentinic hypersensitivity can be defined as pain caused by the dentinal tubules passing all external stimuli to the nerves in the pulp as they are, making them more sensitive to the same stimulus than usual. There is no nerve in the dentin itself, but we feel that it is cold because cold stimuli are transmitted through the dentin tubule to the nerves inside the pulp.
- dentin tubules that run from pulp to enamel.
- the inside of the tube is filled with liquid and has a larger diameter and dense structure toward the pulp, which allows the external stimulus to be quickly transmitted to the inner pulp nerve. If the dentin in contact with the outside is damaged and the area of the dentinal tubule is in contact with the outside, it may be more sensitive than usual to the same stimulus.
- potassium phosphate salt (K 2 HPO 4 ) is widely used as a method for interfering with pain transmission of nerve signaling.
- potassium phosphate salts are not only effective in reducing pain, but also have to be used repeatedly and repeatedly.
- calcium phosphate (CaHPO 4 ), fluorine, oxalate, amino acid arginine and calcium carbonate (CaCO 3 ), etc. are used for the method for blocking ivory tubules.
- calcium phosphate, dentelic type silica, strontium chloride, calcium carbonate or tricalcium phosphate which can treat, alleviate or prevent dentin hypersensitivity, are used as active ingredients.
- Toothpaste-containing toothpaste is being sold, which also uses heterogeneous substances different from the original dentin of the living body, so that over time, a gap is formed in the peripheral boundary or the nerve is exposed again from the blockage. Reducing symptoms of ache, such as the recurrence of ache symptoms have a problem of low efficiency.
- An object of the present invention is to provide a dentifrice composition comprising a peptide that prevents or alleviates perceptual hypersensitivity by closing the defect of the dentin tubule exposed by physiological remineralization of the dentin.
- Toothpaste composition for reducing dentin hypersensitivity hypersensitivity according to an aspect of the present invention for solving the above technical problem provides a toothpaste composition for alleviating dentin hypersensitivity including a peptide consisting of the amino acid sequence of the general formula (1):
- R 1 is arginine (R), lysine (K) or glutamine (Q);
- R2 is arginine (R) or glutamine (Q);
- R3, R4 and R5 are arginine (R) or lysine (K), respectively;
- R6 is asparagine (N) or serine (S);
- R7 and R8 are lysine (K) or tyrosine (Y).
- the peptide may be composed of any one amino acid sequence of SEQ ID NO: 1 to 96.
- 0.0015-0.0025 parts by weight of the peptide may be included based on 100 parts by weight of the composition.
- tricalcium phosphate may be included based on 100 parts by weight of the composition.
- 0.045-0.055 parts by weight of hydroxyapatite may be included based on 100 parts by weight of the composition.
- the dentifrice composition comprises 20-22 parts by weight of purified water, 33-37 parts by weight of wetting agent, 4.4-5.4 parts by weight of viscosity modifier, 1.1-1.3 parts by weight of surfactant, 0.8-flavor based on 100 parts by weight of the composition. .9 parts by weight and 0.04-0.06 parts by weight of excipient.
- the toothpaste composition may include 0.15-0.25 parts by weight of aminokiproic acid and 1.9-2.1 parts by weight of allantoin, based on 100 parts by weight of the composition.
- the wetting agent is D-sorbitol solution or sodium PCA solution, or thick glycerin
- the viscosity modifier is hydrous silicic acid, xanthan gum or CMC
- the surfactant is cocoylmethyltaurine It is sodium acid
- the flavoring agent is green tea extract, chamomile extract, rosemary extract, myrrh tincture, latania tincture, chamomile tink, mastic oil 40 HF-60662, propolis extract, grapefruit seed extract, spearmint B71228 or peppermint oil 81689
- the excipient may be hydroxyapatite.
- the humectant may include 80-83 wt% of the D-sorbitol solution, 7-8 wt% of sodium PAI solution, and 10-12 wt% of concentrated glycerin.
- the viscosity modifier may include 79-85% by weight of the hydrous silicic acid, 4-8% by weight of xanthan gum, 11-13% by weight of the CMC.
- the present invention can provide a dentifrice composition comprising a peptide that prevents or alleviates perceptual hypersensitivity by closing the defect of the dentin tube exposed by physiological remineralization of the dentin.
- Figure 1a is a graph showing the results of comparing the effect of the peptides contained in the toothpaste composition for relieving dentin hypersensitivity according to an embodiment of the present invention on DSPP expression, an odontoblast differentiation marker gene.
- Figure 1b is a graph showing the result of comparing the expression level of the DSPP gene, which is an oblast differentiation marker in the MDPC-23 cells treated with the peptide contained in the toothpaste composition for relieving dentin hypersensitivity according to an embodiment of the present invention.
- DSPP Dmp1, and Nestin genes, which are the oblast differentiation marker genes in MDPC-23 cells treated with peptides of Groups 11 and 12 included in the dentifrice composition for alleviating dentin hypersensitivity according to an embodiment of the present invention. It is a graph showing the result of comparing.
- Figure 1d is a graph showing the results of evaluating the cytotoxicity of the peptides contained in the toothpaste composition for relieving dentin hypersensitivity according to an embodiment of the present invention to the pulp tissue cells.
- Figure 2 is the result of measuring the molecular weight through MALDI-TOF analysis to confirm the stability of the peptide contained in the toothpaste composition for relieving dentin hypersensitivity according to an embodiment of the present invention.
- 2 shows the molecular weight of the peptide itself contained in the dentifrice composition for relieving dentin hypersensitivity according to an embodiment of the present invention.
- 2 shows the molecular weight of the peptide included in the dentifrice composition state for relieving dentin hypersensitivity according to an embodiment of the present invention.
- Figure 3 shows the dentinal tubular permeability of the toothpaste composition for relieving dentin hypersensitivity in accordance with an embodiment of the present invention, by mixing a fluorescent dye reagent (Rhodamine B) treated for 1 minute to the teeth exposed to fluorescence microscope The results observed are shown.
- a fluorescent dye reagent Rhodamine B
- Figure 4 shows the results of comparing the dentin capillary blockage ability of the toothpaste composition for relieving dentin hypersensitivity in accordance with Comparative Example 3-1 and Comparative Example 3-2 and the embodiment of the present invention.
- AD shows the dentin dentinal tubules treated with purified water only
- EH is a toothpaste free of peptide in the composition of the dentifrice composition for relieving dentin hypersensitivity according to an embodiment of the present invention
- IL shows the dentinal brushed brush using the toothpaste composition for alleviating dentin hypersensitivity according to an embodiment of the present invention
- Size bars A, D, G, 100 ⁇ m; B, E, H, 20 ⁇ m; C, F, I, 10 ⁇ m.
- the dentin specimens exposed to ivory tubules were brushed three times with distilled water after brushing for 1 day, once and for 1 minute and stored in artificial saliva. Observed.
- an odontoblast may refer to a cell that synthesizes and secretes proteins and polysaccharides constituting the substrate of the dentin in a cell.
- a columnar cell that forms a layer of cell layers at the periphery of the pulp in contact with the dentin (the calcified dentin), and faces the enamel group of the cells of the dermal papilla (becomes a cell derived from ectoderm mesenchyme).
- Peptides included in the toothpaste composition for relieving dentin hypersensitivity according to an embodiment of the present invention have no cytotoxicity, but do not include cytotoxicity of DSPP, Dmp1 and Nestin genes.
- the expression level may be increased, and when implanted in vivo with pulp tissue cells, the pulp tissue cells may be characterized by forming dentin / dimension-like tissue.
- the odontoblast differentiation peptide also includes a variant peptide having an amino acid sequence which differs from one or more amino acid residues as long as it can exhibit dentin regeneration or therapeutic effect of dentin hypersensitivity.
- amino acid exchange in proteins and polypeptides that do not alter the activity of the molecule as a whole is known in the art.
- the most commonly occurring exchanges are amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Exchange between Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, Asp / Gly.
- the peptide may include a peptide having an increased structural stability against heat, pH, or the like, or an increased regeneration-promoting ability of dentin or pulp tissue due to variation or modification of the amino acid sequence.
- glutamine an acidic amino acid located at No. 3 of the peptide of SEQ ID NO: 1 provided in the present invention
- glutamine an acidic amino acid located at No. 3 of the peptide of SEQ ID NO: 1 provided in the present invention
- glutamine an acidic amino acid located at No. 3 of the peptide of SEQ ID NO: 1 provided in the present invention
- Arginine a basic amino acid located at positions 4 or 5 of the peptide of SEQ ID NO: 1 may exhibit the effect of the peptide provided in the present invention even when substituted with an acidic amino acid glutamine or a basic amino acid lysine
- Lysine a basic amino acid located at Nos.
- the acidic amino acid, basic amino acid or aromatic amino acid constituting the oocyte differentiation-promoting peptide may have the same effect even when substituted with other acidic amino acids, basic amino acids, neutral amino acids or aromatic amino acids, thus constituting the oocyte differentiation promoting peptide. It is apparent that variant peptides having a sequence in which the amino acid sequence differs from one or more amino acid residues are also included in the category of the odontoblast differentiation peptide.
- the peptides provided in the present invention can exhibit the effects of the peptide provided in the present invention.
- the peptide may have a form in which 1 to 300 amino acids are added to the N-terminus or C-terminus of the peptide, and as another example, 1 to 100 amino acids may be added to the N-terminus or C-terminus of the peptide. It may be in an added form, and as another example, may be a form in which 1 to 24 amino acids are added to the N-terminus or C-terminus of the peptide.
- the odontoblast differentiation peptide which has an effect of increasing the mRNA level of the DSPP gene, is known as It has been shown to have an effect of promoting dentin regeneration (Taduru Sreenath et al., THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 27, Issue of July 4, pp. 24874-24880, 2003; William T. Butler et al, Connective Tissue Research, 44 (Suppl. 1): 171-178, 2003).
- Peptides included in the dentifrice composition for relieving dentin hypersensitivity may be used in the form of a peptide alone, the peptide may be used in the form of a polypeptide that is repeatedly connected two or more times, of the peptide It may also be used in the form of a complex in which a drug that exhibits an oblast differentiation or dentin regenerative effect at the N- or C-terminus is bound.
- Peptides (SEQ ID NO: 1) were synthesized by 9-fluorenylmethyloxycarbonyl (Fmoc) method, and the amino acids of the synthesized peptides were substituted to synthesize peptides of each group (Tables 1 to 12).
- the peptide of group 1 was synthesized by substituting lysine or arginine for amino acids 5 to 7 of the peptide of SEQ ID NO: 1 or the peptide of SEQ ID NO: 1 (Table 1).
- the peptide of group 2 was synthesized by substituting lysine or arginine for amino acids 5 to 7 of the peptide of SEQ ID NO: 1 and replacing amino acid 8 with serine (Table 2).
- the peptide of Group 3 was synthesized by substituting amino acids 5 to 7 of the peptide of SEQ ID NO: 1 with lysine or arginine and substituting amino acid 9 with tyrosine (Table 3).
- the peptides of Group 4 replace amino acids 5 to 7 of the peptide of SEQ ID NO: 1 with lysine or arginine, amino acid 8 with serine, amino acid 9 with tyrosine, and amino acid 10 with Synthesis by substitution with lysine (Table 4).
- the peptide of group 5 was synthesized by replacing amino acid 3 of the peptide of SEQ ID NO: 1 with arginine, amino acid 4 with glutamine, and amino acids 5 through 7 with lysine or arginine (Table 5 ).
- the peptide of group 6 replaces amino acid 3 of the peptide of SEQ ID NO: 1 with arginine, amino acid 4 with glutamine, amino acids 5 through 7 with lysine or arginine, and amino acid 8 with Synthesis by substitution with serine (Table 6).
- the peptides of group 7 replace amino acid 3 of the peptide of SEQ ID NO: 1 with arginine, amino acid 4 with glutamine, amino acids 5-7 with lysine or arginine, amino acid 9 Substituted with tyrosine and synthesized by replacing amino acid 10 with lysine (Table 7).
- the peptide of group 8 replaces amino acid 3 of the peptide of SEQ ID NO: 1 with arginine, amino acid 4 with glutamine, amino acids 5 through 7 with lysine or arginine, and amino acid 8 with Substituted with serine, amino acid 9 was replaced with tyrosine and amino acid 10 was replaced with lysine (Table 8).
- the peptide of group 9 was synthesized by replacing amino acid 3 of the peptide of SEQ ID NO: 1 with lysine, amino acid 4 with glutamine, and amino acids 5-7 with lysine or arginine (Table 9 ).
- the peptide of group 10 substitutes lysine for amino acid 3 of the peptide of SEQ ID NO: 1, replaces amino acid 4 with glutamine, replaces amino acids 5-7 with lysine or arginine, and amino acid 8 Synthesis by substitution with serine (Table 10).
- Peptides of group 10 SEQ ID NO: Amino acid sequence (N-C) 7374757677787980 KYKQRKKSKYKYKQRKRSKYKYKQRRKSKYKYKQRRRSKYKYKQKKKSKYKYKQKRKSKYKYKQKKRSKYKYKQKRRSKY
- the peptide of group 11 substitutes lysine for amino acid 3 of the peptide of SEQ ID NO: 1, replaces amino acid 4 with glutamine, replaces amino acids 5-7 with lysine or arginine, and amino acid 9 Substituted with tyrosine and synthesized by replacing amino acid 10 with lysine (Table 11).
- the peptides of group 12 replace amino acid 3 of the peptide of SEQ ID NO: 1 with lysine, amino acid 4 with glutamine, amino acids 5-7 with lysine or arginine, amino acid 8 Substituted with serine, amino acid 9 was replaced with tyrosine and amino acid 10 was replaced with lysine (Table 12).
- Example 2 Verification of the Promoting Effect of Dentin Using Dentin Cells
- Example 2-1 Verification of the Effect of Peptides on the Activity of DSPP (dentin sialophosphoprotein) Promoter
- MDPC-23 cells which are mouse-derived oblasts, were cultured in DMEM medium containing 10% FBS at 5% CO 2 and 37 ° C.
- the cultured MDPC-23 cells were dispensed in a 24-well plate at 5 X 10 4 cells per well, incubated for 24 hours, and then cultured into the cultured cells using lipofectamine Plus TM reagent, pGL3.
- the vector was transformed by introducing a recombinant vector into which the DSPP promoter and luciferase gene were introduced.
- the transformed MDPC-23 cells were treated with the peptides of Groups 1 to 12 synthesized in Example 1 and incubated for 48 hours, and then luciferase activity was measured in each of the transformed MDPC-23 cells. , And compared the average level calculated for each group (Fig. 1a). At this time, the transformed MDPC-23 cells not treated with the odontoblast differentiation peptide were used as a control.
- Figure 1a is a graph showing the results of comparing the effects of each peptide provided by the present invention on DSPP expression, an odontoblast differentiation marker gene for each group.
- each peptide provided in the present invention showed a value of about 1.3 times or more of the luciferase activity level measured in the control group as a whole, but shows a difference for each group, the peptide of the group 12 has the highest Peptides that exhibited levels of luciferase activity and the next highest levels of luciferase activity were identified as group 11 peptides.
- the peptide provided in the present invention was found to exhibit the effect of activating the DSPP promoter.
- the MDPC-23 cells cultured in Example 2-1 were treated with the peptides of each group synthesized in Example 1, incubated for 48 hours, and then were the oblast differentiation marker genes expressed in the MDPC-23 cells.
- MRNA levels of DSPP genes were measured, and the mRNA levels of each of the DSPP genes measured above were converted in relative proportion to the mRNA levels of DSPP genes measured in the control group (Tables 13-24).
- the average value of the mRNA level of the DSPP gene measured according to the peptide of each group was compared for each group (Fig. 1b). In this case, MDPC-23 cells not treated with the odontoblast differentiation peptide were used as controls.
- the synthesized cDNA was used for real time polymerase chain reaction.
- Real-time polymerase chain reaction was performed in ABI PRISM 7500 sequence detection system (Applied Biosystems) using each primer below and SYBR GREEN PCR Master Mix (Takara, Japan).
- Dspp_F 5'-ATTCCGGTTCCCCAGTTAGTA-3 '(SEQ ID NO: 97)
- Gapdh_F 5'-AGGTCGGTGTGAACGGATTTG-3 '(SEQ ID NO: 99)
- Gapdh_R 5'-TGTAGACCATGTAGTTGAGGTCA-3 '(SEQ ID NO: 100)
- Figure 1b is a graph showing the result of comparing the expression level of the DSPP gene, which is an oblast differentiation marker in MDPC-23 cells treated with the oocyte differentiation promoting peptide.
- the treatment of the oocyte differentiation-promoting peptide increases the mRNA level of the DSPP gene, an odontoblast differentiation marker, and similar to that of Figure 1a, a value of about 1.3 times greater than the DSPP gene mRNA level measured in the control group. It was confirmed that it represents.
- Example 2-3 Verification of the Effect of Peptides on the Expression Levels of DSPP, Dmp1, and Nestin Genes, the Tumor Differentiation Marker Gene
- the odontoblast differentiation peptide can increase the mRNA level of the DSPP gene, and in particular, the peptides of groups 11 and 12 can increase the mRNA level of the DSPP gene by at least three times or more. It was confirmed.
- each of the following primers was used, except that the peptides of groups 11 and 12 were used as peptides, followed by the same method as in Example 2-2, and the dendritic cells on the expression level of Dmp1 and Nestin gene The effect of the differentiation-promoting peptides was measured and the average level calculated for each group was compared (FIG. At this time, MDPC-23 cells not treated with the odontoblast differentiation peptide were used as a control group, and mRNA level of DSPP gene was used as a comparison group.
- Dmp1_F 5'-CATTCTCCTTGTGTTCCTTTGGG-3 '(SEQ ID NO: 101)
- Dmp1_R 5'-TGTGGTCACTATTTGCCTGTG-3 '(SEQ ID NO: 102)
- Figure 1c is a graph showing the results of comparing the expression level of the DSPP, Dmp1 and Nestin genes of the odontoblast differentiation marker genes in MDPC-23 cells treated with peptides of groups 11 and 12.
- the treatment of the oocyte differentiation-promoting peptide increased the expression levels of the DSPP, Dmp1 and Nestin genes, which are the oocyte differentiation marker genes, but showed a difference in the level of increase for each gene, rather than the peptide of group 11 It was found that the peptides of group 12 increased to higher levels.
- the differentiation marker genes are known as genes involved in the process of odontoblast differentiation and dentin calcification, the peptide provided in the present invention was analyzed to have an effect of promoting dentin regeneration.
- Example 2-4 Cytotoxicity Evaluation of Peptides for Promoting Regeneration of Dentin or Pulp Tissue and Dentin Hypersensitivity to Pulp Cells
- pulp tissue cells were divided into 96 well plates so as to have a number of about 3 ⁇ 10 3 cells per well, incubated for 24 hours, and then treated with a group 11 or 12 peptide at a concentration of 10 or 50 ⁇ g / ml. And again incubated for 1, 3 or 5 days. After the incubation was terminated, the cultured cells were washed with PBS, 20 ⁇ l of MTT solution was added, and then reacted at about 37 ° C. for 4 hours. After the reaction was completed, the MTT solution was removed, 100 ⁇ l of DMSO was added, and the absorbance was measured at a wavelength of 540 nm (FIG. 1D). In this case, pulp tissue cells cultured without the peptide were used as a control.
- Figure 1d is a graph showing the results of evaluating the cytotoxicity of the odontoblast differentiation peptide against pulp tissue cells. As shown in Figure 1d, it was confirmed that the survival rate of the pulp tissue cells showed the same level as the control group even when the odontoblast differentiation promoting peptide was added.
- Tricalcium phosphate, aminocaproic acid, allantoin, hydrous silicic acid, sodium PCA solution, hydroxyapatite, peptide (SEQ ID NO: 96), enzyme treatment stevia and xylitol were added and stirred for about 40 minutes in a stirrer (stirring condition: PADDLE 10 ⁇ 30 rpm, DISPERSE 500 ⁇ 600 rpm, HOMO 2400 ⁇ 3200 rpm)
- Glycerin and xanthan gum are added and stirred for about 40 minutes (Agitating conditions: PADDLE 10-30 rpm, DISPERSE 500-600 rpm, HOMO 2400-3200 rpm)
- Each step is agitated under reduced pressure (-760 mmHg)
- Composition table of toothpaste compositions for alleviating dentin hypersensitivity according to Example 3 of the present invention division Raw material name Weight (Wt%) One Water Purified water 21.587 Humectant D-sorbitol solution 30 chief ingredient Tricalcium phosphate 32 Aminocaproic acid 0.2 Allantoin 2 Viscosity Modifier Function 4 Humectant Sodium PCA 3 Excipient Hydroxyapatite 0.05 Peptide Odontoblast Differentiation Peptides 0.002 Sweetener Enzyme Treatment Stevia 0.1 Xylitol 0.1 2 Humectant (Rich) glycerin 2 Viscosity Modifier Xanthan Gum 0.3 3 Humectant (Rich) glycerin 2 Viscosity Modifier Carboxymethyl Cellulose Sodium Salt (CMC) 0.6 4 Surfactants Sodium cocoylmethyltaurate 1.2 5 Flavor Green Tea Extract (Organic) 0.01 Chamomile Extract (Organic) 0.01 Rosemary Extract (Organic) 0.01
- Example 3 The components of Example 3 were prepared so that all components other than the purified water were not included in the odontoblast differentiation promoting peptide (SEQ ID NO: 96).
- Toothpaste composition solution was prepared by dissolving about 0.5 g of a sample of the toothpaste composition provided in Example 3 in about 1 ml of distilled water.
- the crown of the extracted tooth is cut horizontally with a diamond saw to expose the ivory tubules and then washed twice with phosphate buffer for about 5 minutes.
- the previously cut tooth was reacted with 0.5 M ethylenediaminetetraacetic acid (EDTA, pH 7.4) solution for about 5 minutes and washed twice with phosphate buffer for 5 minutes.
- EDTA ethylenediaminetetraacetic acid
- Toothpaste composition containing the odontoblast differentiation peptide (SEQ ID NO: 96) is added to the toothpaste composition for alleviation of hypersensitivity of hypersensitivity so that 0.1% of fluorescent dye is included and mixed well.
- the reacted cut teeth were washed three times with distilled water, and then cut into a vertical thickness of about 0.5 mm so that the dentinal tubules of the cut teeth appeared long using a diamond saw (see FIG. 3).
- composition of the artificial saliva is shown in Table 26 below.
- potassium phosphate (K 2 HPO 4 ) was added last.
- ⁇ pH of artificial saliva is measured in the vicinity of 7.2, similar to human saliva.
- a tooth of an extracted person was cut transversely using a diamond saw to fabricate a dentin specimen with 1 mm thick dentinal tubule exposed.
- the dentin specimens were reacted with about 32% phosphoric acid solution for about 5 minutes to fully expose the dentin tubules, and then washed three times with purified water for 5 minutes. Then, the dentin specimens were washed six times in an ultrasonic cleaner for about five minutes to fully expose the dentin tubules.
- the toothpaste composition for alleviating dentin hypersensitivity according to Example 3 was brushed in the dentinal tubule specimens for about 1 minute, washed three times with distilled water, and then reacted with artificial saliva for about 24 hours.
- the toothpaste composition prepared in Comparative Example 3-2 was brushed in ivory tubule specimens for about 1 minute, washed three times with distilled water, and then reacted with artificial saliva for about 24 hours.
- Experimental Example 1 can determine the stability of the peptide contained in the dentifrice composition for relieving dentin hypersensitivity according to the embodiment of the present invention.
- Figure 2 is the result of measuring the molecular weight through MALDI-TOF analysis to confirm the stability of the peptide contained in the toothpaste composition for relieving dentin hypersensitivity according to an embodiment of the present invention.
- 2 shows the molecular weight of the peptide itself contained in the dentifrice composition for relieving dentin hypersensitivity according to an embodiment of the present invention.
- 2 shows the molecular weight of the peptide included in the dentifrice composition state for relieving dentin hypersensitivity according to an embodiment of the present invention.
- Example 2 As a result of observing the dentin tubular permeability of the dentifrice composition for relieving dentin hypersensitivity according to Example 3 with a fluorescence microscope, the dentifrice composition containing the odontoblast differentiation peptide was treated as shown in FIG. In teeth, fluorescence was strongly observed on the dentin surface. In addition, penetration of the fluorescence staining reagent was observed down the exposed ivory tubule.
- FIG. 4 shows the result of comparing the dentin capillary blockade ability of the toothpaste composition for relieving dentin hypersensitivity in accordance with Comparative Example 3-1 and Comparative Example 3-2 and the embodiment of the present invention, more specifically, AD Is an dentinal tubule of dentin treated only with purified water (Comparative Example 3-1), and EH is a toothpaste composition containing no peptide in the composition of the dentifrice composition for relieving dentin hypersensitivity according to the embodiment of the present invention.
- IL shows the dentinal tubules reacted with the dentifrice composition for alleviating dentin hypersensitivity according to an embodiment of the present invention (Size: A, D, G, 100 ⁇ m; B, E, H, 20 ⁇ m; C, F, I, 10 ⁇ m).
- the dentifrice composition for relieving hypersensitivity forms a thin film on dentin and strongly binds to the exposed dentin tube and dentin surface by strongly binding to phosphate-calcium ions liberated from tricalcium phosphate.
- the dentifrice composition for alleviating dentin hypersensitivity exhibits an effect of inducing remineralization not only on the surface of the exposed dentinal tubules but also in the dentinal tubules to alleviate and / or prevent symptomatic symptoms. Can be.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
서열번호 | 아미노산 서열(N-C) |
12345678 | KYQRRKKNKYKYQRRKRNKYKYQRRRKNKYKYQRRRRNKYKYQRKKKNKYKYQRKRKNKYKYQRKKRNKYKYQRKRRNKY |
서열번호 | 아미노산 서열(N-C) |
910111213141516 | KYQRRKKSKYKYQRRKRSKYKYQRRRKSKYKYQRRRRSKYKYQRKKKSKYKYQRKRKSKYKYQRKKRSKYKYQRKRRSKY |
서열번호 | 아미노산 서열(N-C) |
1718192021222324 | KYQRRKKNYKKYQRRKRNYKKYQRRRKNYKKYQRRRRNYKKYQRKKKNYKKYQRKRKNYKKYQRKKRNYKKYQRKRRNYK |
서열번호 | 아미노산 서열(N-C) |
2526272829303132 | KYQRRKKSYKKYQRRKRSYKKYQRRRKSYKKYQRRRRSYKKYQRKKKSYKKYQRKRKSYKKYQRKKRSYKKYQRKRRSYK |
서열번호 | 아미노산 서열(N-C) |
3334353637383940 | KYRQRKKNKYKYRQRKRNKYKYRQRRKNKYKYRQRRRNKYKYRQKKKNKYKYRQKRKNKYKYRQKKRNKYKYRQKRRNKY |
서열번호 | 아미노산 서열(N-C) |
4142434445464748 | KYRQRKKSKYKYRQRKRSKYKYRQRRKSKYKYRQRRRSKYKYRQKKKSKYKYRQKRKSKYKYRQKKRSKYKYRQKRRSKY |
서열번호 | 아미노산 서열(N-C) |
4950515253545556 | KYRQRKKNYKKYRQRKRNYKKYRQRRKNYKKYRQRRRNYKKYRQKKKNYKKYRQKRKNYKKYRQKKRNYKKYRQKRRNYK |
서열번호 | 아미노산 서열(N-C) |
5758596061626364 | KYRQRKKSYKKYRQRKRSYKKYRQRRKSYKKYRQRRRSYKKYRQKKKSYKKYRQKRKSYKKYRQKKRSYKKYRQKRRSYK |
서열번호 | 아미노산 서열(N-C) |
6566676869707172 | KYKQRKKNKYKYKQRKRNKYKYKQRRKNKYKYKQRRRNKYKYKQKKKNKYKYKQKRKNKYKYKQKKRNKYKYKQKRRNKY |
서열번호 | 아미노산 서열(N-C) |
7374757677787980 | KYKQRKKSKYKYKQRKRSKYKYKQRRKSKYKYKQRRRSKYKYKQKKKSKYKYKQKRKSKYKYKQKKRSKYKYKQKRRSKY |
서열번호 | 아미노산 서열(N-C) |
8182838485868788 | KYKQRKKNYKKYKQRKRNYKKYKQRRKNYKKYKQRRRNYKKYKQKKKNYKKYKQKRKNYKKYKQKKRNYKKYKQKRRNYK |
서열번호 | 아미노산 서열(N-C) |
8990919293949596 | KYKQRKKSYKKYKQRKRSYKKYKQRRKSYKKYKQRRRSYKKYKQKKKSYKKYKQKRKSYKKYKQKKRSYKKYKQKRRSYK |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
12345678 | 1.7541.6461.4641.8551.6391.7461.8641.639 | 0.1320.0920.2210.1020.0570.0910.1320.032 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
910111213141516 | 1.8541.7461.6391.5481.6851.8461.9641.739 | 0.0320.0520.2010.0270.0770.1410.2790.092 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
1718192021222324 | 2.1172.3191.9312.5531.8932.4122.1712.212 | 0.2090.0920.1020.0990.1320.0720.2810.111 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
2526272829303132 | 2.3712.1931.9932.4531.8832.5122.3712.219 | 0.0890.0520.2020.1920.1010.2090.1390.302 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
3334353637383940 | 1.7121.9311.9832.3191.5972.1161.7122.219 | 0.0910.1720.1020.2920.3010.2110.1910.212 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
4142434445464748 | 1.5461.5861.6691.7931.5321.8871.6971.558 | 0.0910.1030.0950.2030.3100.0770.0090.201 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
4950515253545556 | 1.9231.8871.6012.0191.5921.4371.6631.701 | 0.1920.0070.0820.1350.2220.3410.0940.109 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
5758596061626364 | 2.0391.9981.7922.1072.3011.6721.7691.967 | 0.0820.1720.0070.2010.0190.3080.0850.039 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
6566676869707172 | 1.7231.6271.7771.4322.0111.9271.8792.011 | 0.0720.2910.0270.4100.0810.1050.0600.009 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
7374757677787980 | 2.0352.0111.9972.3511.7292.6352.2311.837 | 0.0210.0630.0590.1090.1110.0910.0770.201 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
8182838485868788 | 3.0923.3613.5723.7023.6703.7053.8884.021 | 0.1520.0980.2090.3010.0880.1370.0720.301 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
8990919293949596 | 4.2114.8114.3624.2114.5253.8364.6205.211 | 0.4130.3020.1820.2870.2500.0990.4010.371 |
구 분 | 원 료 명 | 중 량(Wt%) | |
1 | 용 수 | 정제수 | 21.587 |
습윤제 | D-소르비톨액 | 30 | |
주성분 | 인산삼칼슘 | 32 | |
아미노카프론산 | 0.2 | ||
알란토인 | 2 | ||
점도조절제 | 함수규산 | 4 | |
습윤제 | 나트륨피씨에이액 | 3 | |
부형제 | 하이드록시아파타이트 | 0.05 | |
펩타이드 | 상아모세포 분화촉진 펩타이드 | 0.002 | |
감미제 | 효소처리스테비아 | 0.1 | |
자일리톨 | 0.1 | ||
2 | 습윤제 | (농)글리세린 | 2 |
점도조절제 | 잔탄검 | 0.3 | |
3 | 습윤제 | (농)글리세린 | 2 |
점도조절제 | CMC(Carboxymethyl Cellulose Sodium Salt) | 0.6 | |
4 | 계면활성제 | 코코일메틸타우린산나트륨 | 1.2 |
5 | 착향제 | 녹차엑스(유기농) | 0.01 |
카모마일추출물(유기농) | 0.01 | ||
로즈마리엑스(유기농) | 0.01 | ||
몰약틴크 | 0.01 | ||
라타니아틴크 | 0.01 | ||
카모밀레틴크 | 0.01 | ||
매스틱오일40 HF-60662 | 0.001 | ||
프로폴리스추출액 | 0.05 | ||
자몽종자추출물 | 0.1 | ||
스피아민트 B71228 | 0.05 | ||
페파민트오일 81689 | 0.6 | ||
합 계 | 100 |
성분 | 농도(mM) |
CaCl2 | 0.7 |
Mgcl2 | 0.2 |
K2HPO4 | 4 |
KCl | 30 |
NaN3 | 0.3 |
HEPES | 20 |
Claims (8)
- 하기 일반식 1의 아미노산 서열로 구성된 펩타이드를 포함하는 상아질 지각과민증 완화를 위한 치약 조성물에 있어서,K-Y-R1-R2-R3-R4-R5-R6-R7-R8 (일반식 1)상기 일반식 1에서,R1은 아르기닌(R), 리신(K) 또는 글루타민(Q)이고;R2는 아르기닌(R) 또는 글루타민(Q)이며;R3, R4 및 R5는 각각 아르기닌(R) 또는 리신(K)이고;R6는 아스파라긴(N) 또는 세린(S)이며; 및R7 및 R8은 리신(K) 또는 타이로신(Y)이고,상기 치약 조성물 100 중량부에 대하여 상기 펩타이드 0.0015-0.0025 중량부, 인산삼칼슘 31.00-33.00 중량부, 하이드록시아파타이트 0.045-0.055 중량부 및 정제수 20-22 중량부를 포함하고,상기 치약 조성물은 상아질 표면에 얇은 막을 형성하고 상기 인산삼칼슘에서 유리된 인산-칼슘 이온과 결합하여 상아세관 및 상아질 표면에 재광화를 유도하는 것을 특징으로 하는 치약 조성물.
- 제1항에 있어서,상기 펩타이드는 서열번호 1 내지 96 중 어느 하나의 아미노산 서열로 구성된 것을 특징으로 하는 상아질 지각과민증 완화를 위한 치약 조성물.
- 제1항에 있어서,상기 조성물 100 중량부에 대하여 습윤제 33-37 중량부, 점도조절제 4.4-5.4 중량부, 계면활성제 1.1-1.3 중량부, 및 착향제 0.8-0.9 중량부를 더 포함하는 것을 특징으로 하는 상아질 지각과민증 완화를 위한 치약 조성물.
- 제1항에 있어서,상기 조성물 100 중량부에 대하여 아미노카프론산 0.15-0.25 중량부, 알란토인 1.9-2.1 중량부를 포함하는 것을 특징으로 하는 상아질 지각과민증 완화를 위한 치약 조성물.
- 제3항에 있어서,상기 습윤제는 D-소르비톨액, 나트륨피씨에이액(sodium PCA Solution), 농글리세린, 또는 이들의 혼합물이고,상기 점도조절제는 함수규산, 잔탄검, CMC, 또는 이들의 혼합물이고,상기 계면활성제는 코코일메틸타우린산나트륨이고,착향제는 녹차엑스, 카모마일추출물, 로즈마리엑스, 몰약틴크, 라타니아틴크, 카모밀레틴크, 매스틱오일40 HF-60662, 프로폴리스추출액, 자몽종자추출물, 스피아민트 B71228, 페파민트오일 81689, 또는 이들의 혼합물인 것을 특징으로 하는 상아질 지각과민증 완화를 위한 치약 조성물.
- 제5항에 있어서,상기 습윤제는 상기 D-소르비톨액 80-83 중량%, 나트륨피씨에이액 7-8 중량%, 농글리세린 10-12 중량%를 포함하는 것을 특징으로 하는 상아질 지각과민증 완화를 위한 치약 조성물.
- 제5항에 있어서,상기 점도조절제는 상기 함수규산 79-85 중량%, 상기 잔탄검 4-8 중량%, 상기 CMC 11-13 중량%를 포함하는 것을 특징으로 하는 상아질 지각과민증 완화를 위한 치약 조성물.
- 제1항에 따른 치약 조성물을 이를 필요로 하는 개체의 구강에 처리하는 단계를 포함하는 상아질 지각과민증 완화 방법.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019265169A AU2019265169B2 (en) | 2018-05-09 | 2019-04-17 | Toothpaste composition for alleviating dentin hypersensitivity |
EP19799399.1A EP3791856A4 (en) | 2018-05-09 | 2019-04-17 | TOOTHPASTE COMPOSITION TO RELIEVE DENTIN SENSITIVITY |
CA3099665A CA3099665C (en) | 2018-05-09 | 2019-04-17 | Toothpaste composition for alleviating dentin hyperesthesia |
RU2020140024A RU2758490C1 (ru) | 2018-05-09 | 2019-04-17 | Композиция зубной пасты для ослабления гиперестезии дентина |
US17/053,404 US11452682B2 (en) | 2018-05-09 | 2019-04-17 | Toothpaste composition for alleviating dentin hyperesthesia |
CN202311480197.9A CN117503628A (zh) | 2018-05-09 | 2019-04-17 | 用于缓解牙本质感觉过敏的牙膏组合物 |
BR112020022685-8A BR112020022685B1 (pt) | 2018-05-09 | 2019-04-17 | Composição de pasta de dentes para aliviar a hiperestesia da dentina e método de alívio da hiperestesia da dentina |
MYPI2020005835A MY193394A (en) | 2018-05-09 | 2019-04-17 | Toothpaste composition for alleviating dentin hyperesthesia |
MX2020011864A MX2020011864A (es) | 2018-05-09 | 2019-04-17 | Composicion de pasta de dientes para aliviar la hiperestesia dentinaria. |
JP2020560366A JP7107600B2 (ja) | 2018-05-09 | 2019-04-17 | 象牙質知覚過敏症緩和のための歯磨き剤組成物 |
CN201980031318.7A CN112105340B (zh) | 2018-05-09 | 2019-04-17 | 用于缓解牙本质感觉过敏的牙膏组合物 |
SG11202011070WA SG11202011070WA (en) | 2018-05-09 | 2019-04-17 | Toothpaste composition for alleviating dentin hyperesthesia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0053013 | 2018-05-09 | ||
KR1020180053013A KR101956579B1 (ko) | 2018-05-09 | 2018-05-09 | 상아질 지각과민증 완화를 위한 치약 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019216568A1 true WO2019216568A1 (ko) | 2019-11-14 |
Family
ID=65758567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/004636 WO2019216568A1 (ko) | 2018-05-09 | 2019-04-17 | 상아질 지각과민증 완화를 위한 치약 조성물 |
Country Status (13)
Country | Link |
---|---|
US (1) | US11452682B2 (ko) |
EP (1) | EP3791856A4 (ko) |
JP (1) | JP7107600B2 (ko) |
KR (1) | KR101956579B1 (ko) |
CN (2) | CN117503628A (ko) |
AU (1) | AU2019265169B2 (ko) |
BR (1) | BR112020022685B1 (ko) |
CA (1) | CA3099665C (ko) |
MX (1) | MX2020011864A (ko) |
MY (1) | MY193394A (ko) |
RU (1) | RU2758490C1 (ko) |
SG (1) | SG11202011070WA (ko) |
WO (1) | WO2019216568A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022138487A1 (ja) * | 2020-12-23 | 2022-06-30 | ライオン株式会社 | 口腔用組成物 |
RU2811919C1 (ru) * | 2020-06-09 | 2024-01-18 | Хайсенсбайо | Фармацевтическая композиция для предотвращения или лечения пародонтоза или травматического вывиха зуба |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101956579B1 (ko) | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 치약 조성물 |
KR101956578B1 (ko) | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 구강 청결용 조성물 |
JP2020070276A (ja) * | 2018-11-02 | 2020-05-07 | ライオン株式会社 | 口腔用組成物 |
KR102299387B1 (ko) | 2019-07-16 | 2021-09-07 | (주)한일제약 | 향균성 치약 조성물 |
KR102474214B1 (ko) | 2022-07-07 | 2022-12-05 | 성현 | 아르기닌을 포함하는 시린 이 증상 완화 기능성 구강용 조성물 |
KR102474196B1 (ko) | 2022-07-07 | 2022-12-06 | 성현 | 글루타민을 포함하는 시린 이 증상 완화 기능성 구강용 조성물 |
KR102596392B1 (ko) * | 2022-12-08 | 2023-11-01 | 주식회사 하이센스바이오 | 신규한 펩타이드 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030152525A1 (en) * | 2002-01-03 | 2003-08-14 | The Procter & Gamble Company | Stable oral compositions comprising casein phosphopeptide complexes and fluoride |
KR20100039750A (ko) * | 2008-10-08 | 2010-04-16 | 서울대학교산학협력단 | 치아 지각과민 방지용 조성물 |
KR20140021142A (ko) * | 2012-08-08 | 2014-02-20 | 서울대학교산학협력단 | 히스톤 탈아세틸화효소 억제제를 포함하는 상아질 재생 촉진용 조성물 및 방법 |
KR20170045246A (ko) * | 2015-01-16 | 2017-04-26 | 가부시키가이샤 상기 | 치약용 조성물 |
KR101772449B1 (ko) * | 2016-12-27 | 2017-08-30 | 주식회사 하이센스바이오 | 신규한 펩타이드 |
KR101956579B1 (ko) * | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 치약 조성물 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624906A (en) * | 1994-12-08 | 1997-04-29 | Lever Brothers Company, Division Of Conopco, Inc. | Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds |
JPH1017449A (ja) | 1996-07-05 | 1998-01-20 | Sangi Co Ltd | 知覚過敏症用組成物 |
JP2003160457A (ja) | 2001-11-27 | 2003-06-03 | Lion Corp | 象牙質知覚過敏予防・治療剤 |
RU2337734C2 (ru) | 2003-02-21 | 2008-11-10 | Родиа Инк. | Ультрамягкое средство для гигиенического ухода за полостью рта против чувствительности, кариеса, окрашивания и зубного налета |
US8557224B2 (en) * | 2003-07-15 | 2013-10-15 | Kao Corporation | Oral cavity composition |
RU2477122C2 (ru) | 2008-02-08 | 2013-03-10 | Колгейт-Палмолив Компани | Композиции и способы с применением пептидов, содержащих основные аминокислоты и протеазы |
EP2281543A1 (en) * | 2009-07-27 | 2011-02-09 | The Procter & Gamble Company | Oral care compositions which comprise stannous and potassium salts |
RU2467739C1 (ru) | 2011-10-31 | 2012-11-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Состав стоматологический для лечения гиперестезии зубов |
CN103417386A (zh) * | 2012-05-25 | 2013-12-04 | 清华大学 | 一种用于治疗牙本质过敏的磷酸钙基齿科修复材料 |
CA2878877C (en) | 2012-08-10 | 2019-11-12 | Colgate-Palmolive Company | Mouthwash comprising peroxy compound, a first acid and a second acid |
AU2012397267B2 (en) | 2012-12-19 | 2015-10-08 | Colgate-Palmolive Company | Oral care compositions comprising zinc amino acid halides |
JP6512218B2 (ja) | 2014-04-21 | 2019-05-15 | ライオン株式会社 | 液体口腔用組成物及びその凍結復元性向上方法 |
CN108348439A (zh) | 2015-10-26 | 2018-07-31 | 巴斯夫欧洲公司 | 包含羟基磷灰石结合蛋白质的口腔护理产品和方法 |
WO2017123986A1 (en) | 2016-01-13 | 2017-07-20 | University Of Washington | Reagents and methods for mineralization of tooth enamel |
CN107400171B (zh) * | 2017-08-30 | 2020-06-23 | 四川大学 | 抗菌和促再矿化双效应防龋多肽、其衍生物和盐及应用 |
KR101943978B1 (ko) | 2017-12-28 | 2019-01-30 | 주식회사 하이센스바이오 | 신규한 펩타이드 |
KR101956578B1 (ko) | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 구강 청결용 조성물 |
-
2018
- 2018-05-09 KR KR1020180053013A patent/KR101956579B1/ko active IP Right Grant
-
2019
- 2019-04-17 CN CN202311480197.9A patent/CN117503628A/zh active Pending
- 2019-04-17 AU AU2019265169A patent/AU2019265169B2/en active Active
- 2019-04-17 BR BR112020022685-8A patent/BR112020022685B1/pt active IP Right Grant
- 2019-04-17 CN CN201980031318.7A patent/CN112105340B/zh active Active
- 2019-04-17 RU RU2020140024A patent/RU2758490C1/ru active
- 2019-04-17 CA CA3099665A patent/CA3099665C/en active Active
- 2019-04-17 US US17/053,404 patent/US11452682B2/en active Active
- 2019-04-17 EP EP19799399.1A patent/EP3791856A4/en active Pending
- 2019-04-17 JP JP2020560366A patent/JP7107600B2/ja active Active
- 2019-04-17 MY MYPI2020005835A patent/MY193394A/en unknown
- 2019-04-17 WO PCT/KR2019/004636 patent/WO2019216568A1/ko unknown
- 2019-04-17 MX MX2020011864A patent/MX2020011864A/es unknown
- 2019-04-17 SG SG11202011070WA patent/SG11202011070WA/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030152525A1 (en) * | 2002-01-03 | 2003-08-14 | The Procter & Gamble Company | Stable oral compositions comprising casein phosphopeptide complexes and fluoride |
KR20100039750A (ko) * | 2008-10-08 | 2010-04-16 | 서울대학교산학협력단 | 치아 지각과민 방지용 조성물 |
KR20140021142A (ko) * | 2012-08-08 | 2014-02-20 | 서울대학교산학협력단 | 히스톤 탈아세틸화효소 억제제를 포함하는 상아질 재생 촉진용 조성물 및 방법 |
KR20170045246A (ko) * | 2015-01-16 | 2017-04-26 | 가부시키가이샤 상기 | 치약용 조성물 |
KR101772449B1 (ko) * | 2016-12-27 | 2017-08-30 | 주식회사 하이센스바이오 | 신규한 펩타이드 |
KR101956579B1 (ko) * | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 치약 조성물 |
Non-Patent Citations (4)
Title |
---|
JUNG HS ET AL., J MOL HISTOL, 2011 |
See also references of EP3791856A4 |
TADURU SREENATH ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 27, 4 July 2003 (2003-07-04), pages 24874 - 24880 |
WILLIAM T. BUTLER ET AL., CONNECTIVE TISSUE RESEARCH, vol. 44, 2003, pages 171 - 178 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2811919C1 (ru) * | 2020-06-09 | 2024-01-18 | Хайсенсбайо | Фармацевтическая композиция для предотвращения или лечения пародонтоза или травматического вывиха зуба |
WO2022138487A1 (ja) * | 2020-12-23 | 2022-06-30 | ライオン株式会社 | 口腔用組成物 |
Also Published As
Publication number | Publication date |
---|---|
RU2758490C1 (ru) | 2021-10-28 |
AU2019265169A1 (en) | 2020-11-26 |
KR101956579B1 (ko) | 2019-03-11 |
SG11202011070WA (en) | 2020-12-30 |
MX2020011864A (es) | 2021-01-20 |
MY193394A (en) | 2022-10-11 |
EP3791856A1 (en) | 2021-03-17 |
AU2019265169B2 (en) | 2022-11-10 |
CN112105340A (zh) | 2020-12-18 |
CN117503628A (zh) | 2024-02-06 |
JP2021519811A (ja) | 2021-08-12 |
JP7107600B2 (ja) | 2022-07-27 |
CA3099665C (en) | 2023-08-01 |
CA3099665A1 (en) | 2019-11-14 |
CN112105340B (zh) | 2023-11-28 |
US11452682B2 (en) | 2022-09-27 |
BR112020022685A2 (pt) | 2021-02-17 |
BR112020022685B1 (pt) | 2023-12-26 |
EP3791856A4 (en) | 2022-04-20 |
US20210369584A1 (en) | 2021-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019216568A1 (ko) | 상아질 지각과민증 완화를 위한 치약 조성물 | |
WO2019103203A1 (ko) | 신규 펩티드 및 이를 포함한 조성물 | |
WO2018124425A1 (ko) | 신규한 펩타이드 | |
WO2019132352A1 (ko) | 신규한 펩타이드 | |
WO2016137162A1 (ko) | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 | |
WO2015156649A1 (ko) | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 | |
WO2016190660A1 (ko) | 신규 펩티드 및 이를 포함한 조성물 | |
WO2021251673A1 (ko) | 치주질환 또는 탈구성 외상 치아의 예방 또는 치료용 약학 조성물 | |
WO2018155997A1 (ko) | 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용 | |
WO2018012848A1 (ko) | 후박 추출물 및 신이 추출물의 혼합물을 유효성분으로 함유하는 치주조직 성장 촉진용 및 치주염 예방 또는 치료용 약학적 조성물 | |
WO2019216567A1 (ko) | 상아질 지각과민증 완화를 위한 구강 청결용 조성물 | |
WO2018088813A9 (ko) | Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물 | |
WO2018056706A1 (ko) | 티오레독신 결합단백질 유래 펩타이드 또는 이를 암호화 하는 폴리뉴클레오타이드를 유효성분으로 함유하는 노화 줄기세포의 역노화용 조성물 및 이의 용도 | |
WO2021251789A1 (ko) | 펜타펩타이드를 유효성분으로 포함하는 조성물 | |
WO2016167600A1 (ko) | 구강용 조성물 | |
WO2019132353A1 (ko) | Cpne4 단백질을 포함하는 상아질-치수질환 또는 치주질환 예방 또는 치료용 약학적 조성물 | |
WO2016027990A1 (ko) | Dusp5를 유효성분으로 모두 포함하는 골대사성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2021251790A1 (ko) | 항비만 활성을 가지는 디옥시콜산-펩타이드 결합체 및 이의 용도 | |
WO2024058315A1 (ko) | Cpne7 유래 펩타이드를 포함하는 상아질 접착용 조성물 및 치수복조용 조성물 | |
WO2024122889A1 (ko) | 신규한 펩타이드 | |
WO2023171900A1 (ko) | 치아우식증 예방 또는 치료용 조성물 | |
WO2024122722A1 (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
WO2019039630A1 (ko) | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 | |
WO2023172004A1 (ko) | 수복 상아질 재생 활성을 갖는 펩타이드 및 이의 용도 | |
WO2024072143A1 (ko) | 4r 타우병증의 치료 또는 예방용 펩티드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19799399 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020560366 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3099665 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020022685 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019265169 Country of ref document: AU Date of ref document: 20190417 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019799399 Country of ref document: EP Effective date: 20201209 |
|
ENP | Entry into the national phase |
Ref document number: 112020022685 Country of ref document: BR Kind code of ref document: A2 Effective date: 20201106 |